BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27161970)

  • 21. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
    Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
    Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?
    Hahn EE; Tang T; Lee JS; Munoz-Plaza CE; Shen E; Rowley B; Maeda JL; Mosen DM; Ruckdeschel JC; Gould MK
    Cancer; 2016 Mar; 122(6):908-16. PubMed ID: 26650715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications.
    De Placido S; De Angelis C; Giuliano M; Pizzi C; Ruocco R; Perrone V; Bruzzese D; Tommasielli G; De Laurentiis M; Cammarota S; Arpino G; Arpino G
    Br J Cancer; 2017 Mar; 116(6):821-827. PubMed ID: 28170371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
    Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
    Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030.
    Gogate A; Wheeler SB; Reeder-Hayes KE; Ekwueme DU; Fairley TL; Drier S; Trogdon JG
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
    Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 30. Mammography use, breast cancer stage at diagnosis, and survival among older women.
    McCarthy EP; Burns RB; Freund KM; Ash AS; Shwartz M; Marwill SL; Moskowitz MA
    J Am Geriatr Soc; 2000 Oct; 48(10):1226-33. PubMed ID: 11037009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
    Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer.
    Carlson JJ; Guzauskas GF; Dann RA; Ramsey SD
    J Med Econ; 2021; 24(1):1309-1317. PubMed ID: 34763605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downstream Breast Imaging Following Screening Mammography in Medicare Patients with Advanced Cancer: A Population-Based Study.
    Sadigh G; Duszak R; Ward KC; Jiang R; Switchenko JM; Applegate KE; Carlos RC
    J Gen Intern Med; 2018 Mar; 33(3):284-290. PubMed ID: 29139055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of illness associated with metastatic breast cancer.
    Rao S; Kubisiak J; Gilden D
    Breast Cancer Res Treat; 2004 Jan; 83(1):25-32. PubMed ID: 14997052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
    Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
    JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Pennant M; Takwoingi Y; Pennant L; Davenport C; Fry-Smith A; Eisinga A; Andronis L; Arvanitis T; Deeks J; Hyde C
    Health Technol Assess; 2010 Oct; 14(50):1-103. PubMed ID: 21044553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.
    Morris PG; Lynch C; Feeney JN; Patil S; Howard J; Larson SM; Dickler M; Hudis CA; Jochelson M; McArthur HL
    J Clin Oncol; 2010 Jul; 28(19):3154-9. PubMed ID: 20516453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
    Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
    Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
    [No Abstract]   [Full Text] [Related]  

  • 40. Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer.
    Doshi SD; DeStephano D; Accordino MK; Elkin E; Raghunathan RR; Wright JD; Hershman DL
    Breast Cancer Res Treat; 2024 Jan; 203(1):111-119. PubMed ID: 37688666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.